Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Peptide patents



      

This page is updated frequently with new Peptide-related patent applications.




Date/App# patent app List of recent Peptide-related patents
06/23/16
20160178642 
 Biomarkers for cognitive dysfunction diseases and  detecting cognitive dysfunction disease using biomarkers patent thumbnailBiomarkers for cognitive dysfunction diseases and detecting cognitive dysfunction disease using biomarkers
Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein a1 comprising the amino acid sequence represented by seq id no:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by seq id no:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement c3 comprising the amino acid sequence represented by seq id no:3 or a partial peptide thereof..

06/23/16
20160178627 
 System and  identification and characterization of transglutaminase species patent thumbnailSystem and identification and characterization of transglutaminase species
In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases..

06/23/16
20160178612 
 Differential bh3 mitochondrial profiling patent thumbnailDifferential bh3 mitochondrial profiling
The present invention relates to methods of determining cancer cell sensitivity to treatment by correlating the pattern of sensitivity of the cell to a panel of bh3 domain peptides. The invention also provides a method applying an algorithm to said pattern to predict therapeutic efficacy and of monitoring the shift in cell sensitivity to a therapeutic during treatment..

06/23/16
20160178611 
 Three-dimensional transglutaminase-crosslinked hydrogel for tumor engineering patent thumbnailThree-dimensional transglutaminase-crosslinked hydrogel for tumor engineering
Development of a physiologically relevant 3d model system for cancer research and drug development represents quite a challenge. We have adopted a 3d culture system based on a transglutaminase-crosslinked gelatin gel (col-tgel) to mimic tumor 3d microenvironment.

06/23/16
20160177404 
 Cannabis genomes and uses thereof patent thumbnailCannabis genomes and uses thereof
Using the efficiency of next generation sequencing, a draft de novo reference sequence for the cannabis (c.) sativa and c. Indica genomes has been generated as well as four full length contiguous sequences with homology to thca and cbda synthases and 10 partially homologous contigs with truncated orfs.

06/23/16
20160177390 
 Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease patent thumbnailGenetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease. The present disclosure provides a method of treating a patient with alzheimer's disease (ad) or a subject susceptible to developing ad, comprising: (a) assaying a sample obtained from an early-stage ad patient or a subject susceptible to developing ad for the presence of a brain-derived neurotrophic factor (bdnf) gene mutation and/or a protein tyrosine phosphatase receptor-type, z polypeptide 1 (ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (aβ), wherein the presence of brain aβ in combination with the bdnf gene and/or ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat ad with rapid cognitive decline..

06/23/16
20160177369 
 Resonance energy transfer assay with cleavage sequence and spacer patent thumbnailResonance energy transfer assay with cleavage sequence and spacer
A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of cfp-(sglrsra)-snap-25-(sns)-yfp, and cfp-(sglrsra)-synaptobrevin-(sns)-yfp.

06/23/16
20160177360 
 Microorganisms for diterpene production patent thumbnailMicroorganisms for diterpene production
The present invention relates to a recombinant microorganism comprising one or more nucleotide sequence(s) encoding: a polypeptide having ent-copalyl pyrophosphate synthase activity; a polypeptide having ent-kaurene synthase activity; a polypeptide having ent-kaurene oxidase activity; and a polypeptide having kaurenoic acid 13-hydroxylase activity, whereby expression of the nucleotide sequence(s) confer(s) on the microorganism the ability to produce at least steviol. The recombinant microorganism may also be capable of expressing one or more udp-glucosyltransferases such that the microorganism is capable of producing one or more steviol glycosides..

06/23/16
20160177343 
 Polypeptides having glucoamylase activity and polynucleotides encoding same patent thumbnailPolypeptides having glucoamylase activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..

06/23/16
20160177333 
 Pesticidal genes and methods of use patent thumbnailPesticidal genes and methods of use
Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptides having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the polypeptides, dna constructs and vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the polypeptides.

06/23/16
20160177332 

Axmi281 toxin gene and methods for its use


Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.

06/23/16
20160177328 

Plants having one or more enhanced yield-related traits and a making the same


A method for enhancing various economically important yield-related traits in plants. A method for enhancing one or more yield-related traits in plants by modulating expression in plants of a nucleic acid encoding a fkbp 16-3 (fk506-binding protein) or a quinone reductase-related (qrr) polypeptide.

06/23/16
20160177319 

Increasing the expression of a transgene in eukaryotic cells by reducing rna interference


Described are methods for increasing the expression of a transgene in eukaryotic cells by reducing rna interference (rnai), and variant cells produce by the method. The methods and variant cells are useful, for example, for the efficient production of therapeutic and industrial polypeptides in eukaryotic cells..

06/23/16
20160177318 

Novel selection vectors and methods of selecting eukaryotic host cells


Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.. .

06/23/16
20160177309 

Antisense molecules for treatment for treatment of staphylococcus aureus infection


Disclosed are antisense molecules and compositions for the treatment of staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as rna, dna, or nucleic acid molecules with modified backbones, such as pna.

06/23/16
20160177299 

Compositions and methods using capsids resistant to hydrolases


Novel processes and compositions are described which use viral capsid proteins resistant to hydrolases to prepare virus-like particles to enclose and subsequently isolate and purify target cargo molecules of interest including nucleic acids such as sirnas and shrnas, mirnas, messenger rnas, small peptides and bioactive molecules.. .

06/23/16
20160177297 

Antisense molecules for treatment of staphylococcus aureus infection


Disclosed are antisense molecules and compositions for the treatment of staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as rna, dna, or nucleic acid molecules with modified backbones, such as pna.

06/23/16
20160177293 

Modified peptide display


The invention provides a replicable genetic package displaying a cyclic peptide having at least one intramolecular bond between amino acid side chains. Also provided are a method of preparing such a genetic package displaying cyclic peptides having at least one intramolecular bond.

06/23/16
20160177292 

Method for screening catalytic peptides using phage display technology


A method for screening catalytic peptides using phage display technology is disclosed. A compound is exposed to a phage library.

06/23/16
20160177288 

Method for producing alpha-santalene


The present invention provides a method of producing α-santalene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). In particular, the method may be carried out in vitro or in vivo to produce α-santalene, a very useful compound in the fields of perfumery and flavoring.

06/23/16
20160177284 

Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions


The present invention provides cell-targeted molecules comprising binding regions for cell-type specific targeting and shiga toxin a subunit effector regions for shiga toxin effector functions, wherein the shiga toxin effector regions are at and/or proximal to an amino-terminus of a polypeptide component of the cell-targeted molecule, and optionally comprising a disrupted, furin-cleavage motif between the shiga toxin effector region and the binding region. The cell-targeted molecules of the invention exhibit a more optimized cytotoxicity and/or improved, in vivo tolerability as compared to related molecules comprising less amino-terminus proximal, shiga toxin effector regions and/or furin-cleavage sensitive, wild-type, shiga toxin effector regions.

06/23/16
20160177282 

Polypeptides having cellobiohydrolase i activity and polynucleotides encoding same


The present invention relates to polypeptides having cellobiohydrolase i activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides..

06/23/16
20160177277 

Mutants of cocaine esterase


Provided are mutant cocaine esterase polypeptides and pegylated formulations thereof.. .

06/23/16
20160176983 

Intercalated single-chain variable fragments


Single chain antibody polypeptides with engineered peptide bond crossovers in the light chain and/or heavy chain variable domains, compositions comprising the same, and methods of making and using the same are provided. The antibody polypeptides can be intercalated (crossover) single chain variable fragments (scfvs) or any antibody frameworks which comprise such scfvs, such as diabodies, bispecific antibodies or bssfvs.

06/23/16
20160176975 

Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies


The present invention provides a method for inducing a cancer specific immune response against muc1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide.

06/23/16
20160176970 

Peptide or peptide complex binding to alpha2 integrin and methods and uses involving the same


The present invention relates to a peptide or peptide complex binding to α2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting α2 integrin and a screening method.. .

06/23/16
20160176954 

Anti-c5 antibodies and methods of use


An objective of the invention is to provide anti-c5 antibodies and methods of using the same. The invention provides anti-c5 antibodies and methods of using the same.

06/23/16
20160176952 

Phage displaying system expressing single chain antibody


Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries.

06/23/16
20160176951 

Synthetic library of specific binding molecules


The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (i): fw 1-cdr1-fw2-hv2-fw3a-hv4-fw3b-cdr3-fw4 comprising (1) isolating rna from a member of a species in the elasmobranchii subclass; (2) amplifying dna sequences from rna obtained; (3) selecting a dna sequence from the database prepared; (4) amplifying dna sequences encoding two or more contiguous peptide domains of fw1-cdr1-fw2-hv2-fw3a-hv4-fw3b-cdr3-fw4; (5) ligating together said amplified dna sequences to form dna sequences encoding an antigen specific binding molecule; (6) cloning the amplified dna obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules. The invention also provides methods for the production of an antigen specific antigen binding molecule as defined, pharmaceutical compositions comprising such molecules and uses thereof in medicine..

06/23/16
20160176950 

Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods


The invention provides a polypeptide containing at least one igg fc region, wherein said at least one igg fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.. .

06/23/16
20160176948 

Thrombospondin-1 polypeptides and methods of using same


The invention features thrombospondin-1 (tsp-1) polypeptides (e.g., 3tsr-fc fusion proteins), nucleic acid molecules encoding the tsp-1 polypeptides, and compositions thereof. The invention also features methods of making and using the tsp-1 polypeptides of the invention (e.g., using 3tsr-fc fusion proteins to treat a subject having a disorder associated with pathological angiogenesis, e.g., cancer, e.g., epithelial ovarian cancer (eoc))..

06/23/16
20160176944 

Oligomeric receptor ligand pair member complexes


This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric mhc-peptide complex in particular and a method of labeling, detecting and separating mammalian t cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell.

06/23/16
20160176943 

Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof


The present invention relates to novel alternative splice transcripts (ast) for mica (mhc class i related chain alpha) encoding novel mica protein isoforms and uses thereof. In particular, the present invention relates to an isolated polypeptide at least 80% of identity with a sequence selected from the group consisting of seq id no:1 (mica-a), seq id no:2 (mica-b1), seq id no:3 (mica-b2); seq id no:4 (mica-c) and seq id no: (mica-d)..

06/23/16
20160176940 

Recombinant protein


A recombinant protein is provided. The recombinant protein of the invention comprises an erythropoietin and a highly glycosylated peptide, and has a longer half-life.

06/23/16
20160176939 

Cancer antigen helper peptide


The present invention relates to a wt1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a wt1 protein and induces wt1-specific helper t cells by binding to an mhc class ii molecule, a pharmaceutical composition comprising them and the like.. .

06/23/16
20160176938 

Partial region polypeptide of reic/dkk-3 protein


A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and dna encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the reic/dkk-3 protein..

06/23/16
20160176937 

Short peptides derived from vdac1, compositions and methods of use thereof


The present invention relates to short peptides based on the amino acids sequence of the n-terminal domain of the human mitochondrial protein voltage-dependent anion channel 1 (vdac) and to peptide conjugates having a cell permeability enhancing moiety. The peptides, peptide conjugates and pharmaceutical compositions containing them are useful for treating diseases characterized by cell hyperproliferation or resistance to cell death and in particular, cancer..

06/23/16
20160176936 

Mps peptides and use thereof


This disclosure provides an isolated polypeptide comprising no more than 35 amino acids, wherein the amino acid sequence comprises, or alternatively consists essentially of, or alternatively consisting of xxxrysyxxsyx (seq id no: 1) and equivalents thereof, wherein x is a basic amino acid and y is a hydrophobic amino acid. Polynucleotides encoding the polypeptides and antibodies that bind to the polypeptides are also provided.

06/23/16
20160176935 

Filip1l compositions and methods for treating cancer


A purified doc1 polypeptide comprising a fragment of seq id no: 1 is provided, wherein the doc1 polypeptide is not the full-length doc1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a doc1 polypeptide, whereby a cell in the subject produces the doc1 polypeptide, thus inhibiting angiogenesis.

06/23/16
20160176932 

Stabilized soluble pre-fusion rsv f polypeptides


This disclosure provides stable pre-fusion respiratory syncytial virus (rsv) f polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of rsv infection.. .

06/23/16
20160176931 

Red genetically encoded calcium indicators and methods of use


Protein indicators useful for calcium imaging, in particular, red genetically-encoded calcium indicators (gecis) disclosed herein rival best-of-class green gecis in terms of sensitivity for detecting neural activity, and can be monitored in vivo. The presently-disclosed subject matter further includes a method of monitoring cell activity comprising stimulating a cell comprising a red geci polypeptide; and detecting fluorescence emitted by the cell..

06/23/16
20160176930 

Mu opioid receptor agonist analogs of the endomorphins


The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a d-amino acid substitution in position 2.

06/23/16
20160176929 

Bradykinin receptor modulators and use thereof


The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.. .

06/23/16
20160176928 

Immunomodulators


The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .

06/23/16
20160176927 

Peptide for suppressing osteoclast differentiation and use thereof


The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.

06/23/16
20160176926 

Peptides and related molecules that bind to tall-1


Wherein v1 is a vehicle that is covalently attached to one or more of the above tall-1 modulating compositions of matter. The vehicle and the tall-1 modulating composition of matter may be linked through the n- or c-terminus of the tall-1 modulating portion.

06/23/16
20160176925 

Melanocortin receptor ligands modified with hydantoin


The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .

06/23/16
20160176924 

Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction


The present invention is directed to the provision of small molecule inhibitors of the psd-95/nmda receptor interaction, employing an undecapeptide corresponding to the c-terminal of the nmda as a template for finding lead candidates. A compound (nmdar/psd-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence ytxv or ysxv, wherein y is selected from among e, q, and a, or an analogue thereof, and x is selected from among a, q, d, n, n-me-a, n-me-q, n-me-d, and n-me-n or an analogue thereof, wherein an amino-terminal residue of the peptide is n-alkylated.

06/23/16
20160176923 

Nonapeptide with anti-tumour activity


The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.. .

06/23/16
20160176918 

Coupling peptide synthesis at elevated temperatures


An improved method for coupling carboxylic acids and amines is disclosed that includes the steps of combining a hyper-acid sensitive linker connecting an amine and a resin, a carboxylic acid, a carbodiimide, an activator additive, and a base, and carrying out the activation and coupling at a temperature greater than 30° c.. .

06/23/16
20160175459 

Il-15 and il-15raplha sushi domain based modulokines


The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .

06/23/16
20160175457 

Ocular device


The present invention relates to a composition, such as a coating composition, comprising a peptide linked to a lubricant, wherein the peptide is cleavable by one or more proteinases present in tear fluid. The invention further relates to an ocular device comprising said composition, such as a preformed contact lens..

06/23/16
20160175456 

Peptide sequence design and use thereof for peptide-mediated sirna delivery


Peptides that have been found to facilitate the delivery of sirna molecules into cells and to function in sirna mediated silencing of cellular targets are disclosed. Complexes that include one of the peptides and a cargo molecule are disclosed, wherein the peptide and the cargo molecule are coupled non-covalently.

06/23/16
20160175455 

Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules


The present invention relates to a nanocomplex useful for efficient transfection and delivery of biomolecules comprising amphipathic peptide sequence. The invention more particularly relates to the development of amphipathic peptides for the delivery of biomolecules to the eukaryotic cells.

06/23/16
20160175426 

Compositions for mucusal delivery, useful for treating papillomavirus infections


Polypeptides, compositions, and methods for treatment of papillomavirus (pv) infections including a papillomavirus (pv) minor capsid (l2) polypeptide fragment and a cholera toxin b subunit (ctb) polypeptide are described. Polypeptides and compositions disclosed herein can be administered to the mucosa of a subject, resulting in unexpectedly beneficial production of cross-neutralizing antibodies..

06/23/16
20160175424 

Haemophilus influenzae type iv pili


The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.

06/23/16
20160175413 

Method and composition for treating sarcopenia


A method of treating sarcopenia comprises immunizing a subject in need thereof against age-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an age antigen.

06/23/16
20160175405 

Fusion proteins and methods for treating hiv infection and aids related symptoms


Pharmaceutical compositions and methods for using a fusion protein having a superoxide dismutase and a transit peptide are described. Pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with aids or htv infection are also described..

06/23/16
20160175400 

Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides


Methods are provided for administering an extended half-life glp-1/gip coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.. .

06/23/16
20160175399 

Il-13 receptor binding peptides


A targeting peptide that specifically binds to an il13 receptor (e.g., wherein said targeting peptide is not an il13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule.

06/23/16
20160175396 

Methods for treating or preventing fatty liver disease using ctrp3


Methods are disclosed for treating or preventing fatty liver disease using a ctrp3 polypeptide or functional variant thereof.. .

06/23/16
20160175389 

New peptides having specificity for the lungs


The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there.

06/23/16
20160175386 

Immunomodulators


The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .

06/23/16
20160175384 

Melanotropin ligands for skin care


A melanocortin 1 receptor (mc1r) peptide ligand-elastic vesicle complex. The mc1r peptide ligand is modified by coupling the mc1r ligand to a functionality or linker, such as a click functionality, for conjugation to a surface or agent.

06/23/16
20160175379 

Combination therapy for the treatment of ischemia-reperfusion injury


The present technology provides methods of preventing or treating an ischemia-reperfusion injury, such as acute myocardial infarction injury, in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and a second active agent to subjects in need thereof..

06/23/16
20160175357 

Novel immunotherapy against neuronal and brain tumors


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

06/23/16
20160175263 

Pharmaceutical composition for preventing or treating diabetes mellitus, preventing or treating diabetes mellitus, and screening for diabetes mellitus therapeutic agent


Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering the individual with a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition, and a screening method of an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (glp-1) secreted from the cell; and determining the test material, when the test material promotes expression of glp-1, as a candidate material of an antidiabetic agent. In addition, a quasi-drug composition and a cosmetic composition including geraniol for uses are provided..

06/23/16
20160175249 

Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a treatment of multiple sclerosis


Wherein p1 is an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of seq id nos:1-3; each of r1 and r2 are amino acid sequences independently consisting of from 1 to 10 amino acids; and each of a and b are independently zero or one. Compositions of immunodominant peptides of myelin basic protein are encapsulated in mannosylated liposomes.

06/23/16
20160175247 

Composition containing polycationic triblock copolymer, polyanionic polymer and physiologically active peptide


Peg is a segment that contains poly(ethylene glycol).. .

06/23/16
20160175246 

Pharmaceutical formulations


Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material.

06/23/16
20160175226 

Stabilized calcium phosphate complexes


The present invention relates to a phosphopeptide-stabilized amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complex, wherein the complex is formed at a ph of below 7.0. Methods of making such complexes are also provided.

06/23/16
20160175225 

Peptides and their use in the treatment of skin


Embodiments of the invention are related generally to the methods of diminishing the signs of aging in and/or improving health of human integuments, such as skin, and compositions comprising peptides useful therefor. The compositions according to the invention may comprise one or more peptides or fragments or derivatives thereof derived from a growth factor, e.g., growth differentiation factor 11 (gdf11), in a topically acceptable vehicle..

06/23/16
20160175224 

Antiperspirant composition


The present invention relates to a topical antiperspirant composition comprising a cosmetically acceptable topical carrier and an anticholinergic agent selected from the group consisting of acetyl octapeptide-3 and dipeptide diaminobutyroyl benzylamide diacetate in an amount effective to inhibit or prevent perspiration, wherein said composition is substantially free of aluminum salts.. .





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Peptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peptide with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7954

5282

1 - 1 - 118